Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

with PR) were subsequently treated with Zevalin therapy. Consolidation with Zevalin converted 12 of 14 partial remissions (86 percent) to complete remissions for a complete response rate of 96 percent. With a median follow-up of 30 months, estimated three-year progression-free survival (PFS) was 76 percent and estimated three-year overall survival 100 percent. Twenty two percent of patients tested (5 of 23) achieved a molecular remission following chemotherapy. Zevalin consolidation induced a molecular remission in 14 of 18 patients (78 percent) tested who did not achieve a molecular remission after fludarabine-mitoxantrone therapy. Grade 3/4 thrombocytopenia, neutropenia, and anemia occurred in 63 percent (36 of 57), 53 percent (30 of 57), and 23 percent (13 of 57), respectively. Febrile neutropenia occurred in 9 percent (5 of 57) of patients. Patients who relapsed were treated with CHOP + rituximab as salvage therapy and all tolerated six cycles of therapy indicating that treatment with Zevalin did not preclude the ability to administer an aggressive salvage regimen.

Details of the Study

The phase II trial, reported by P.L. Zinzani et. al. from the Institute of Hematology and Medical Oncology at the University of Bologna in Bologna Italy, was a prospective, single-arm, open-label, multi-center, non-randomized trial, known as FLUMIZ (FLUdarabine, MItoxantrone, Zevalin). The trial was conducted at 13 Italian institutions to evaluate the efficacy and safety of this regimen as first-line therapy in untreated patients with follicular non-Hodgkin's lymphoma. Patients with stage III or IV untreated indolent follicular NHL were treated with oral fludarabine and intravenous mitoxantrone every 28 days for six cycles. Patients who had at least a partial response with adequate platelet counts (>100x10^9/L) and granulocyte counts (1.5x10^9/L), and bone marrow tumor infiltration of less than 25 percent four to six weeks after completion of the sixth cycle of chem
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... /PRNewswire/ -- Treatment of,coronary artery disease (CAD) appears to ... study published today in The,American Journal of Cardiology. , ... 10.6 percent from 2002 to 2005, possibly due,to broader ... as well as declines in risk factors like smoking. ...
... Research from Non-clinical Studies Presented at the ... Symposia Molecular,Targets for Cancer Meetings Support Phase ... March 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... SNS-314, at,two leading scientific meetings focused on ...
Cached Medicine Technology:Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
(Date:7/11/2014)... the hot Texas sun won’t keep kids from having fun ... school had previously invested in a playground structure to augment ... asked for an innovative solution to help protect children from ... a Rectangular Shade from APCPLAY as the perfect solution to ... The shade measures 24’W x 34’H x 11’H to fully ...
(Date:7/11/2014)... 2014 Shu Cosmetic Surgery announces ... each qualifying patient undergoing a laser vaginal ... laser vaginal rejuvenation, an advanced type of vaginal ... procedure decreases the internal and external diameters of ... strength, and control, resulting in enhanced sexual gratification ...
(Date:7/11/2014)... ASHBURN PSYCHOLOGICAL AND PSYCHIATRIC SERVICES , On ... with an intellectual disability or autism to have a special ... cards to alert law enforcement or first responders that they ... was inspired by a central Virginia mother, Ms. Pam Mines, ... old autistic son, JP. During a news conference after ...
(Date:7/10/2014)... Karen Middleton, Executive Director of NARAL ... Planned Parenthood of the Rocky Mountains (PPRM), gave the ... Representative Diana DeGette were in Washington, DC today to ... and keeping bosses out of women’s birth control decisions: ... president today in Denver addressing issues related to the ...
(Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
Breaking Medicine News(10 mins):Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 3Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2
... June 22 Providence Tarzana Medical Center on Friday became ... in imaging - the Ziehm Vision RFD - in this case ... a patient who had suffered a small stroke. , , ... at Tarzana, liked what he saw in the crystal-clear image provided ...
... , British Journal of Dermatology study blames physician misdiagnosis as ... , WASHINGTON, June 22 A newly released study ... data from a 13-year period in the eastern United Kingdom ... be real. , , The study attributed the ...
... The Department of Veterans Affairs (VA) has initiated a large, ... health issues that may affect Operation Enduring Freedom/Operation Iraqi Freedom ... time period. VA,s "National Health Study for a New ... to OEF/OIF and 30,000 comparison Veterans who were not deployed. ...
... attend field hearing exploring use of Recovery Act funds , ... Benjamin L. Cardin (D-MD ), chaired a field hearing today ... in Rockville, MD, entitled " Missed Opportunities: The ARRA ... and national experts in biotechnology testified about the important research ...
... Health and Sustainable Communities , , LOS ANGELES, June ... National Association of Latino Elected and Appointed Officials (NALEO), a ... and deepen their understanding of critical policy issues, will take ... Los Angeles, California. , , The NALEO ...
... don,t socialize regularly risk losing motor function, researchers say ... people who don,t socialize much might be increasing their ... researchers from Rush University Medical Center report. , On ... and mentally tend to stave off the decline in ...
Cached Medicine News:Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:VA Launches 10-Year Health Study of 60,000 New Veterans 2Health News:Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 2Health News:Top Obama Administration Officials to Engage Latino Leaders on Critical Policy Issues in Los Angeles This Week 2Health News:Top Obama Administration Officials to Engage Latino Leaders on Critical Policy Issues in Los Angeles This Week 3Health News:Social Activity Keeps Elders Young, Agile 2Health News:Social Activity Keeps Elders Young, Agile 3
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
... The BrachySource iodine-125 implant is a combination ... remarkable visibility that makes BrachySource I-125 implant ... You can be confident that every BrachySource ... seed management services which is required by ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: